Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Japan or Australia.
This communication is not offering material and is for information purposes only.
Paris, January 25th, 2012
STENTYS launches a private placement of up to 10% of capital STENTYS S.A. ("STENTYS" or the "Company") announces today the launch of a capital increase without preferential subscription rights exclusively reserved to qualified investors through an accelerated book- building for an amount of up to 10% of the share capital (the "Private Placement"). The Private Placement will be conducted in the European Economic Area and Switzerland, not including the United States of America, Canada, Australia and Japan and in accordance with Article L.411-2 II of the French Monetary and Financial Code. STENTYS will use the net proceeds of the capital increase to continue its clinical and commercial development in Europe and in the United States of America. In connection with the Private Placement, the Company has entered into a 90-day lock-up agreement pursuant to which it has agreed not to issue or sell any ordinary STENTYS shares as from the settlement and the delivery of the Private Placement. The Private Placement will be conducted, subject to the satisfaction of certain standard conditions, by way of an accelerated bookbuilding process carried out by Société Générale Corporate & Investment Banking and Kempen & Co (the "Joint-Lead Managers and Joint-Bookrunners") to French and international qualified investors. The bookbuilding will commence immediately and is expected to end at or before 17:30 CET 26 January 2012. The bookbuilding process may, however, be closed earlier at any time during the bookbuilding period at the sole discretion of the Joint-Lead Managers and Joint-Bookrunners. The number and price at which the shares are to be offered will be agreed by the Company and the Joint-Lead Managers and Joint-Bookrunners at the close of the book-building process. Details of the number of shares and the placing price will be announced as soon as practicable after the close of the book-building process.About STENTYS:
Based in Paris (France) and Princeton, N.J. (USA), the
STENTYS Company has developed a new generation of stents to
treat acute myocardial infarction. Founded by Jacques Séguin,
Professor of Cardiac Surgery, and Gonzague Issenmann, STENTYS
received the CE mark for its flagship products in 2010. Its
self-apposing stents adapt the anatomic changes of the
arteries in the post-infarction phase and prevents
conventional stents mal-apposition problems. STENTYS has
started its marketing activities in several European
countries.
More information about the
company on the website: www.stentys.com
STENTYS Stanislas Piot CFO
Tel.: +33 (0)1 44 53 99 42 investors@stentys.com
NewCap.
Investor Relations
Axelle Vuillermet / Pierre Laurent Tel. : +33 (0)1 44 71 94 94 stentys@newcap.fr
STENTYS is listed on NYSE Euronext Paris (Compartment C) ISIN: FR0010949404 - Ticker: STNT
Page 1/2
Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Japan or Australia.
This communication is not offering material and is for information purposes only.
Disclaimer
This announcement does not, and shall not, in any
circumstances, constitute a public offering nor an offer to
subscribe nor an invitation to the public in any jurisdiction
in connection with any offer.
This press release does not constitute or form part of an
offer or solicitation of an offer to subscribe for securities
in France. The securities referred to herein may not be and
will not be offered or sold to the public in France except to
qualified investors, acting for their own account, as defined
in, and in accordance with Articles L. 411-2 II and D. 411-1
to D. 411-3 of the French Monetary and Financial Code.
With respect to the member states of the European Economic
Area which have implemented the Directive 2003/71/EC of the
European Parliament and the Council of November 4, 2003, as
amended, in particular by Directive 2010/73/EC of the
European Parliament and of the Council of November 24, 2010
(the "Prospectus Directive"), no action has been
undertaken or will be undertaken to make an offer to the
public of the securities referred to herein requiring a
publication of a prospectus in any relevant member state. As
a result, the securities may not and will not be offered in
any relevant member state except in accordance with the
exemptions set forth in Article 3(2) of the Prospectus
Directive, if they have been implemented in that relevant
member state, or under any other circumstances which do not
require the publication by STENTYS of a prospectus pursuant
to Article 3 of the Prospectus Directive and/or to applicable
regulations of that relevant member state.
This announcement and the information contained herein do not
constitute an offer or solicitation of an offer to subscribe
for securities in the United States or any other
jurisdiction. Securities may not be offered or sold in the
United States absent registration or an exemption from
registration under the U.S. Securities Act of 1933, as
amended (the "U.S. Securities Act"). The shares of STENTYS
have not been and will not be registered under the U.S.
Securities Act and STENTYS does not intend to register
securities or conduct a public offering in the United
States.
In the United Kingdom, this document is only being
distributed to, and is only directed at, persons that are
"qualified investors" within the meaning of Article
2(1)(e)(i), (ii) or (iii) of the Prospectus Directive and
that also (i) are "investment professionals"
falling within Article 19(5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005 (as
amended, the "Order"), (ii) are persons falling
within Article 49(2)(a) to (d) ("high net worth
companies, unincorporated associations, etc.") of the
Order, or (iii) are persons to whom an invitation or
inducement to engage in investment activity (within the
meaning of section 21 of the Financial Services and Markets
Act 2000) in connection with the issue or sale of any
securities may otherwise lawfully be communicated or caused
to be communicated (all such persons together being referred
to as "relevant persons"). In the United Kingdom,
this document is directed only at relevant persons and must
not be acted on or relied on by persons who are not relevant
persons. Any investment or investment activity to which this
document relates is available only to relevant persons and
will be engaged in only with relevant persons.
The distribution of this announcement in certain countries
may be subject to specific regulations. The persons in
possession of this announcement shall then get knowledge of
any local restrictions and shall comply with these
restrictions.
Any decision to subscribe for shares STENTYS should only be
made on the basis of public information about STENTYS. This
information does not fall under the responsibility of Société
Générale Corporate & Investment Banking and Kempen & Co and
have not been independently verified by Société Générale
Corporate & Investment Banking and Kempen & Co.
No copy of this announcement has been or should be
distributed or sent to the United States, Canada, Japan or
Australia.
Page 2/2
distribué par | Ce noodl a été diffusé par Stentys SA et initialement mise en ligne sur le site http://www.stentys.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-25 19:38:01 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |
Documents associés | |
25 January 2012: Private placement |